Physician profile

Robert Michael Friedmeyer

Adolescent Medicine (Pediatrics) · Valrico, FL

NPI 1184623068

$460.62

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$292.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ironshore Pharmaceuticals INC. $125.50 2019-2023 Jornay Pm
Pfizer INC. $89.88 2020-2024
Merck Sharp & Dohme LLC $80.89 2020-2024 Gardasil 9, Gardasil, M-M-R II
Cranial Technologies, INC $59.15 2020-2023 Doc Band
Sitesaver INC. $50.00 2022
Supernus Pharmaceuticals, INC. $39.24 2023 Qelbree
Glaxosmithkline, LLC. $15.96 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Michael Friedmeyer

$460.62

in general payments reported 2019-2025

Years
2019-2024
Top company
Ironshore Pharmaceuticals INC.

https://glasscript.com/doctor/280161/robert-michael-friedmeyer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.